S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
US gas prices have fallen or remained steady for 10 weeks straight. Here's why
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
US gas prices have fallen or remained steady for 10 weeks straight. Here's why
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
US gas prices have fallen or remained steady for 10 weeks straight. Here's why
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
US gas prices have fallen or remained steady for 10 weeks straight. Here's why

Premier (PINC) Stock Forecast & Price Target

$20.69
-0.18 (-0.86%)
(As of 11/28/2023 ET)
Compare
Today's Range
$20.61
$20.80
50-Day Range
$19.01
$21.99
52-Week Range
$18.89
$35.57
Volume
661,579 shs
Average Volume
790,114 shs
Market Capitalization
$2.47 billion
P/E Ratio
13.98
Dividend Yield
4.06%
Price Target
$27.50

Premier Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$27.50
32.91% Upside
High Forecast$42.00
Average Forecast$27.50
Low Forecast$21.00
TypeCurrent Forecast
11/29/22 to 11/29/23
1 Month Ago
10/30/22 to 10/30/23
3 Months Ago
8/31/22 to 8/31/23
1 Year Ago
11/29/21 to 11/29/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$27.50$29.64$29.64$39.88
Predicted Upside32.91% Upside14.69% Upside14.69% Upside15.04% Upside
Get Premier Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PINC and its competitors with MarketBeat's FREE daily newsletter.


PINC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PINC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Premier Stock vs. The Competition

TypePremierMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.67
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside32.91% Upside1,019.61% Upside2,838.33% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$26.00 ➝ $21.00+8.19%
11/9/2023Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$32.00 ➝ $30.00+55.84%
8/24/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$30.00 ➝ $24.00+9.64%
8/24/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$33.00 ➝ $25.00+14.21%
8/23/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$29.00 ➝ $26.00+8.11%
8/23/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$38.00 ➝ $30.00+24.74%
8/23/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderperform ➝ Underperform$31.00 ➝ $26.00+8.11%
8/23/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$44.00 ➝ $25.00+3.95%
5/3/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$31.00 ➝ $26.00-3.56%
5/2/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
2/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$46.00 ➝ $42.00+27.16%
(Data available from 11/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PINC Price Target - Frequently Asked Questions

What is Premier's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Premier stock is Hold based on the current 1 sell rating, 6 hold ratings and 3 buy ratings for PINC. The average twelve-month price prediction for Premier is $27.50 with a high price target of $42.00 and a low price target of $21.00. Learn more on PINC's analyst rating history.

Do Wall Street analysts like Premier more than its competitors?

Analysts like Premier less than other Medical companies. The consensus rating for Premier is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how PINC compares to other companies.

Does Premier's stock price have much upside?

According to analysts, Premier's stock has a predicted upside of 16.03% based on their 12-month stock forecasts.

What analysts cover Premier?

Premier has been rated by Benchmark, and JPMorgan Chase & Co. in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PINC) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -